Proposed Potential Medical Applicationa of ZKCPr1
- Treat excess visceral fat with a commercially feasible low dose of ZKCPr1 with a
primary focus on the normal-weight or overweight elderly who has difficulty exercising
and who are not candidates of receiving an obesity drug that, in any case, probably
would be less efficient for that purpose compared to ZKCPr1. Presently there is no
competition for such market
- Use low dose of ZKCPr1 for co-treatment of obese people already treated with and
obesity drug who could profit from a greater reduction of visceral fat. Such treatment
would also strongly reduce high triglyceride levels and significantly reduce the loss
of muscle proteins and muscle mass resulting in more mobility. In addition, ZKCPr1 could
help those on statins by adding a strong effect on triglycerides (which statins alone
can’t provide)
- Use ZKCPr1 as a maintenance therapy for those who cannot tolerate an obesity drug
any longer but want to avoid regaining excess visceral fat
- Use low dose ZKCPr1 as co-treatment when an antidiabetic drug alone is insufficient
to maintain blood glucose target
- In case of obese and seriously diabetic cancer patients on insulin therapy, use low
dose ZKCPr1 to both reduce visceral fat as well as the dose and frequency of insulin use
(or perhaps even replacing insulin), thus, also reducing the known tumor promoting effect
of this hormone as an additional benefit
Home
Major Results
Mechanism
Applications
Advisors
Management
Contact Us
